Obesity: an Underappreciate Risk Factor for Severe Form of COVID-19

March 15, 2023 updated by: Younes Oujidi, Mohammed VI University Hospital

Obesity: an Underappreciate Risk Factor for Severe Form of COVID-19: Retrospective Cohort Study of 415 Cases

Our study has the objective of identifying the epidemiological profil of the patients, as well as, the clinical, radiological and prognosis of obese patients with covid 19.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Introduction: COVID 19 pandemic continues to progress with a considerable mortality and morbidity throughout the world since its emergence in December 2019. Many studies were conducted to identify the predictive factors of mortality of those infected with the virus. The previous studies noticed that obesity seems to be associated with severe form of respiratory distress syndrome. Our study has the objective of identifying the epidemiological profil of the patients, as well as, the clinical, radiological and prognosis of obese patients with covid 19.

Methods: investigators led a retrospective monocentric, descriptive and analytic study, in the department of anesthesia and intensive care unit of the university hospital of Mohamed VI Oujda, in Morocco, from March 2020 to October 2021, including all the patients tested positive for the infection.

Study Type

Observational

Enrollment (Actual)

415

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Morocco
      • Berkane, Morocco, 9999
        • younes Oujidi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

investigators have included all the patients presenting an infection with SARS-CoV-2 (1069 patients) diagnosed following the regarding of the world health organization (WHO), confirmed by a PCR of a nasopharyngeal swap, or highly suspected images on thoracic CT scans, that were hospitalized in the intensive care unit.

Description

Inclusion Criteria:

  • All patients presenting an infection with SARS-CoV-2 that were hospitalized in the intensive care unit.

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Obesity: An underappreciate risk factor for severe form of COVID-19: Retrospective cohort study of 415 cases
Time Frame: in all the 22 mounths
Is obesity a predictive factor of need of intensive care, in addition to the mortality of covid 19?
in all the 22 mounths
Risk factor for severe form of COVID-19
Time Frame: in all the 22 mounths
identify the epidemiological profil of the patients, as well as, the clinical, radiological and prognosis of obese patients with covid 19.
in all the 22 mounths

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mohammed VI University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2020

Primary Completion (Actual)

September 30, 2021

Study Completion (Actual)

October 1, 2021

Study Registration Dates

First Submitted

March 14, 2023

First Submitted That Met QC Criteria

March 15, 2023

First Posted (Actual)

March 16, 2023

Study Record Updates

Last Update Posted (Actual)

March 16, 2023

Last Update Submitted That Met QC Criteria

March 15, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Service anesthesie Reanimation

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Obesity

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe